NASDAQ:INCYIncyte Stock Price, Forecast & News

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INCY shares have increased by 41.7% and is now trading at $101.91. View which stocks have been most impacted by Coronavirus.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 9 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Incyte.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) announced its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, missing the consensus estimate of $0.31 by $3.17. The biopharmaceutical company earned $568.51 million during the quarter, compared to the consensus estimate of $553.24 million. Incyte had a negative net margin of 16.87% and a negative return on equity of 12.81%. Incyte's revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.62 EPS. View Incyte's earnings history.

21 brokers have issued 1 year price objectives for Incyte's shares. Their forecasts range from $79.00 to $121.00. On average, they expect Incyte's share price to reach $99.42 in the next year. This suggests that the stock has a possible downside of 2.4%. View analysts' price targets for Incyte.

Headlines about INCY stock have been trending positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Incyte earned a daily sentiment score of 2.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutIncyte.

Incyte saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 7,230,000 shares, an increase of 17.6% from the April 15th total of 6,150,000 shares. Based on an average trading volume of 2,020,000 shares, the days-to-cover ratio is currently 3.6 days. Approximately 3.4% of the company's stock are sold short. View Incyte's Current Options Chain.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Micron Technology (MU), Array Biopharma (ARRY) and Celgene (CELG).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.06%), Capital International Investors (4.36%), State Street Corp (3.85%), Invesco Ltd. (1.52%), Geode Capital Management LLC (1.38%) and AQR Capital Management LLC (0.99%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Jean Jacques Bienaime, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View institutional ownership trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Nicholas Investment Partners LP, Two Sigma Investments LP, Alliancebernstein L.P., Squarepoint Ops LLC, and Invesco Ltd.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Dashyant Dhanak, Jean Jacques Bienaime, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon, and Yao Wenqing. View insider buying and selling activity for Incyte.

INCY stock was purchased by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, Camber Capital Management LP, NWQ Investment Management Company LLC, First Trust Advisors LP, Eaton Vance Management, Sector Gamma AS, and PGGM Investments. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Jean Jacques Bienaime. View insider buying and selling activity for Incyte.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $101.91.

Incyte has a market capitalization of $22.15 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

The official website for Incyte is www.incyte.com.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]